Campbell & CO Investment Adviser LLC grew its position in shares of Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 56.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,235 shares of the company’s stock after acquiring an additional 9,791 shares during the quarter. Campbell & CO Investment Adviser LLC’s holdings in Henry Schein were worth $1,990,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in HSIC. ANTIPODES PARTNERS Ltd acquired a new position in Henry Schein during the second quarter worth $43,000. Steph & Co. bought a new stake in Henry Schein during the 2nd quarter worth about $44,000. CX Institutional lifted its position in Henry Schein by 107.3% during the 2nd quarter. CX Institutional now owns 651 shares of the company’s stock worth $48,000 after buying an additional 337 shares in the last quarter. TD Private Client Wealth LLC boosted its stake in shares of Henry Schein by 103.0% during the 2nd quarter. TD Private Client Wealth LLC now owns 668 shares of the company’s stock worth $49,000 after buying an additional 339 shares during the last quarter. Finally, Whittier Trust Co. grew its holdings in shares of Henry Schein by 714.3% in the 1st quarter. Whittier Trust Co. now owns 798 shares of the company’s stock valued at $55,000 after acquiring an additional 700 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.
Henry Schein Stock Performance
NASDAQ HSIC opened at $73.00 on Tuesday. The stock has a market cap of $8.59 billion, a PE ratio of 23.55, a P/E/G ratio of 2.06 and a beta of 0.84. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.78 and a current ratio of 1.41. The firm has a 50-day moving average of $66.37 and a 200-day moving average of $68.81. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $82.49.
Analysts Set New Price Targets
Several analysts recently issued reports on HSIC shares. JPMorgan Chase & Co. upped their target price on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. UBS Group lowered their price target on Henry Schein from $75.00 to $70.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Baird R W downgraded Henry Schein from a “strong-buy” rating to a “hold” rating in a report on Monday, July 14th. Leerink Partners set a $75.00 target price on shares of Henry Schein in a research note on Monday, July 14th. Finally, Robert W. Baird restated a “neutral” rating and set a $72.00 target price (down from $82.00) on shares of Henry Schein in a report on Monday, July 14th. Five investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $76.08.
Read Our Latest Stock Analysis on HSIC
Henry Schein Profile
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Stories
- Five stocks we like better than Henry Schein
- Canada Bond Market Holiday: How to Invest and Trade
- Insiders Sold Big at These 3 Stocks—Should You Worry?
- The How And Why of Investing in Oil Stocks
- Shares Down, Price Targets Up: 3 Stocks Upgraded After +10% Drops
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Nuclear Stocks Are Melting Down—Should Investors Panic?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
